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Abstract
Background: Cytosine modifications in DNA such as 5-methylcytosine (5mC)
underlie a broad range of developmental processes, maintain cellular lineage
specification, and can define or stratify types of cancer and other diseases. However,
the wide variety of approaches available to interrogate these modifications has
created a need for harmonized materials, methods, and rigorous benchmarking to
improve genome-wide methylome sequencing applications in clinical and basic
research. Here, we present a multi-platform assessment and cross-validated resource
for epigenetics research from the FDA’s Epigenomics Quality Control Group.
Results: Each sample is processed in multiple replicates by three whole-genome
bisulfite sequencing (WGBS) protocols (TruSeq DNA methylation, Accel-NGS
MethylSeq, and SPLAT), oxidative bisulfite sequencing (TrueMethyl), enzymatic
deamination method (EMSeq), targeted methylation sequencing (Illumina Methyl
Capture EPIC), single-molecule long-read nanopore sequencing from Oxford
Nanopore Technologies, and 850k Illumina methylation arrays. After rigorous quality
assessment and comparison to Illumina EPIC methylation microarrays and testing on
a range of algorithms (Bismark, BitmapperBS, bwa-meth, and BitMapperBS), we find
overall high concordance between assays, but also differences in efficiency of read
mapping, CpG capture, coverage, and platform performance, and variable
performance across 26 microarray normalization algorithms.
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Conclusions: The data provided herein can guide the use of these DNA reference
materials in epigenomics research, as well as provide best practices for experimental
design in future studies. By leveraging seven human cell lines that are designated as
publicly available reference materials, these data can be used as a baseline to
advance epigenomics research.
Introduction
DNA methylation plays a key role in the regulation of gene expression [1], disease on-
set [2], cellular development [1], age progression [3], and transposable element activity
[4]. Whole-genome bisulfite sequencing (WGBS) is increasingly used for fundamental
and clinical research of CpG methylation. Numerous validated protocols and commer-
cially available kits are available for WGBS library preparation ([5–7]). Other assays to
interrogate the epigenome include oxidative bisulfite sequencing [8], enzymatic de-
amination [9], and targeted approaches ([10, 11]), further accelerating the breadth and
rate of discovery in genome-wide DNA methylation studies.
As the field of epigenomics continues to advance, there is a need to establish defini-
tive standards and benchmarks representative of the methylome. In recent years, the
Genome in a Bottle (GIAB) Consortium has established seven human cell lines as refer-
ence material to enable genomics benchmarking and discovery [12]. Recent studies
have characterized the genomes of these cell lines (e.g., germline structural variant de-
tection in [13]), but none yet have examined the epigenome. Here, the FDA’s Epige-
nomics Quality Control (EpiQC) Group presents DNA methylation sequence data
across all seven GIAB reference cell lines, as well as a comparative analysis of targeted
and genome-wide methylation protocols, to serve as a comprehensive resource for epi-
genetics research. We build on top of work done in previous studies to compare the
performance and biases of WGBS library kits (e.g., [6, 14, 15]) by evaluating both com-
monly used and newly available epigenomic library preparation kits. We report the
relative performance of each kit, as measured by mapping efficiencies, CpG coverage,
and methylation estimates. We then characterize the reproducibility and challenges of
methylation estimation across the genome. We further sequenced these cell lines using
long-read technology on an Oxford Nanopore PromethION and here compare its per-
formance alongside more common chemical/enzymatic conversion kits and short-read
sequencing. Finally, we generated microarray data for these cell lines and provide
guidelines for normalization of beta values, site filtration, and comparison to sequence
data. This reference dataset can act as a benchmarking resource and a reference point
for future studies as epigenetics research becomes more widespread within the field of
genomics.
Results
Study design and sequencing outputs
We generated epigenomic data for seven well-characterized human cell lines (HG001-
HG007) that have been designated as reference materials for genomic benchmarking by
the Genome in a Bottle (GIAB) Consortium [12]. These cell lines include NA12878
(HG001) from the CEPH Utah Reference Collection, as well as two family trios from
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the Personal Genome Project, one of Ashkenazi Jewish ancestry (HG002-4) and one of
Han Chinese ancestry (HG005-7).
Libraries for whole epigenome sequencing were prepared using a variety of common bi-
sulfite and enzymatic conversion kits, including NEBNext Enzymatic Methyl-Seq (referred
to here as EMSeq), Swift Bio sciences Accel-NGS Methyl-Seq (MethylSeq), SPlinted
Ligation Adapter Tagging (SPLAT), NuGEN TrueMethyl oxBS-Seq (TrueMethyl), and
Illumina TruSeq DNA Methylation (TruSeq). Cell line genomic DNA was acquired from
Coriell, and one aliquot of each genome was extracted and distributed to six independent
laboratories, each utilizing one library preparation method (Table 1).
Each site prepared two technical replicates per cell line for their respective epigenetic
assay. In the case of EMSeq, libraries were prepared at two sites, designated as Lab 1
and Lab 2. All other sites were designated as Lab 1 for their library type. In the case of
TrueMethyl, pairs of replicates were made using a bisulfite-only treatment (BS) and an
oxidative bisulfite treatment (OX). All libraries were pooled into equimolar concentra-
tions and sequenced in multiplex at one site (see “Methods”), resulting in a range of
500M to 3.5B paired-end reads per replicate. The range of sequencing depth per repli-
cate resulted from an imbalance in library pooling, as well as differences in shearing
condition and size selection per library type (see “Methods”). In addition to short-read
sequencing of epigenetic libraries, Oxford Nanopore R9.4.1 PromethION flow cells (re-
ferred to here as Nanopore) were run to generate long read sequence data for each gen-
ome, each ranging from 75B to 250B bases.
Data quality control
We performed quality control of all sequence data generated within this study using
FASTQC [16] (see Supplementary Data 1 for quality reports for every sample). As a
measure of the success of the bisulfite or enzymatic conversion step of each library
preparation, we estimated the cytosine conversion rate across CpG and non-CpG con-
texts (Additional file 1: Figure S1a). CpG methylation levels fell in the expected 45–
65% range across all libraries (Methyl Capture EPIC, as an exception, showed lower
rates, a reflection of targeting less methylated regions such as promoters and
Table 1 Sequencing across all genomes analyzed in this study, including genomic and targeted
assays. Numbers within each genome/assay cell indicate millions of paired-end 150bp reads
sequenced, with the exception of PromenthION, which indicates millions of reads and mean read
length in parentheses. Each number represents one replicate sequenced for that genome/assay
Foox et al. Genome Biology          (2021) 22:332 Page 3 of 30
enhancers). We detected near zero non-CpG methylation as expected for all libraries,
though CHG and CHH context conversion was somewhat elevated for TruSeq libraries
(Additional file 1: Figure S1a) (see below for mapping and methylation calling that en-
abled these estimates).
Depending on library preparation, different libraries had different completely
unmethylated (lambda) or completely methylated (pUC19 plasmid) spiked-in controls
(see “Methods”). Methylation levels of these controls were very nearly 0% or 100% re-
spectively across all libraries (Additional file 1: Figure S1b), further reflecting the quality
of the data.
Mapping efficiencies
Following quality control, we examined the performance of reference-based read align-
ment and methylation estimation for samples of each library type. Our pipeline of
choice was bwa-meth (a common methylation aware, reference-based read aligner)
followed by MethylDackel for methylation extraction. This combination was chosen for
its high mapping efficiency, greatest mean depth of coverage per CpG, and computa-
tional speed (for a comparison of alignment and methylation calling pipelines, see the
supplementary results, as well as Additional file 1: Figure S2 and Additional file 1: Fig-
ure S3). Each epigenomic assay had a distinct profile of mapping outcomes (Fig. 1a).
MethylSeq had the highest primary mapping rate and lowest secondary/unmapped rate.
While EMSeq (Lab 1) and SPLAT had comparable primary mapping rates to Methyl-
Seq, SPLAT had the highest fraction of unmapped reads. TrueMethyl had the highest
rate of multi-mapped reads, while TruSeq returned the highest rate of PCR duplicate
reads.
As a measure of protocol efficiency, we estimated the total cytosine conversion in
CpG contexts and found that each whole methylome approach converted 45–65% of
CpGs. As an estimate of conversion efficiency, we also characterized methylation in
CHG and CHH contexts and found methylation rates for all libraries to be close to the
expected 0% range (nearing 100% conversion efficiency), except for TruSeq which
neared 2% in CHG contexts and 1% in CHH contexts, and MethylSeq which
approached 0.75% in CHH contexts (Additional file 1: Figure S1).
Each assay had a specific, tight profile of insert size distributions (Fig. 1b). There was
a strong relationship within each assay between the estimated insert size and the per-
centage of total bases that were trimmed prior to alignment (this included trimming
adapter content, low-quality bases, and dovetailing bases between mates of a pair of
reads). Libraries with insert sizes below 275 bp had anywhere from 5 to 25% of total
bases trimmed, while EMSeq libraries with > 275 bp insert sizes needed very few bases
trimmed other than adapter content (Fig. 1c). This was due to the 150 × 150 chemistry
used for sequencing, and the threshold for fragment size may be lower with shorter
read sequencing.
Imbalanced base trimming and unequal distribution of reads per replicate (see above)
resulted in divergent genome coverage per assay (Fig. 1d). Generally, a minimum of
20× coverage is considered sufficiently deep to characterize a genomic region, and
EMSeq and MethylSeq had the highest percentage of the genome covered at 20×. This
was followed by SPLAT, the oxidative and bisulite replicates of TrueMethyl, and lastly
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Fig. 1 (See legend on next page.)
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the TruSeq libraries, which had the lowest percentage of the genome covered at lower
depths, but a long tail of high-coverage sites. TruSeq libraries also showed a high de-
gree of dinucleotide bias favoring GC-rich regions compared to other libraries (Fig. 1e),
owing to the GC-biased random hexamer ligation step in its library preparation, as well
as exposing samples to sodium bisulfite prior to DNA shearing.
Reads from whole methylome libraries were passed through an alignment and methylation
calling pipeline (see above). Reads were filtered from the methylation calling process if they
did not map to the reference genome, if they were marked as a non-primary alignment (sec-
ondary/supplementary/duplicate reads), or if they were assigned a mapping quality score
below MQ10. The fractions of reads that were filtered along the alignment pipeline (Add-
itional file 1: Figure S4) were highly assay-specific. At the end of this process, EMSeq libraries
retained the highest percentage of reads for methylation calling (maximum 86%), followed by
SPLAT (83%), MethylSeq (81%), TrueMethyl (80%), and finally TruSeq (77%). EMSeq also
showed laboratory specificity, with lower rates of usable bases in libraries prepared using
shorter fragment sizes (mean of 86% in Lab 1 versus 73% in Lab 2) (see “Methods”). We ob-
served no notable differences in read filtration rates between TrueMethyl libraries treated with
potassium perruthenate (KRuO4) oxidation and those only exposed to sodium bisulfite. The
average percentage of usable bases is summarized per assay for HG002 in Table 2, and more
detailed statistics for all cell lines are shown in Additional file 2: Supplementary Table 2.
We next calculated for each library type the relationship between raw total number of
read pairs sequenced versus the mean depth of coverage achieved per CpG (Fig. 1f). We
found that the rates were highly assay-specific, as seen above. Overall, in order to achieve a
target mean depth of 20× per CpG, EMSeq required the fewest reads (275–300M read
pairs), followed by MethylSeq (366M) and SPLAT (369M), then TruSeq (461M), and then
TrueMethyl (692M), as noted in Table 2. In order to compare short-read data to long read
data of variable length from Oxford Nanopore, we calculated the same relationship using
total bases sequenced (Fig. 1g). We found that nanopore sequencing covered CpGs and
called methylation at a similar rate per nucleotide, comparable to short-read libraries.
CpG coverage and downsampling
We next analyzed the distribution of CpG coverage across the genome per assay. In
order to control for the effect of uneven sequencing depth, we first downsampled the
(See figure on previous page.)
Fig. 1 Sequencing and alignment metrics of whole methylome libraries, including all replicates across all
cell lines. EM = EMSeq; MS = MethylSeq; SP=SPLAT; TS = TruSeq; TM = TrueMethyl. a Distribution of
reference-based read alignment outcomes, including primary mapped reads (both mates mapped in
correct orientation within a certain distance), multi-mapped reads (read pairs containing secondary or
supplementary alignments), reads marked as PCR or optical duplicates, and unmapped reads. Ambiguous
and duplicate reads can be a subset of properly aligned reads. b Median insert size distributions derived
from distance between aligned paired end reads. c Percentage of bases trimmed per replicate, either due
to low base quality, adapter content, or dovetailing reads. d Cumulative genomic coverage plot, averaged
across cell line per assay. Coverage is cut off at 200× in this plot, but extends beyond for all assays. Dotted
line indicates 20× mean coverage. e Nucleotide bias plot showing the log2 enrichment of covered versus
expected mono- and di-nucleotides. f The relationship between the number of read pairs sequenced per
assay and the mean depth of coverage per CpG dinucleotide, showing sequencing depth required to
achieve a certain level of coverage. 20× CpG coverage is shown as the dotted line. g Same as f, but plotted
using total bases sequenced, to include Oxford Nanopore sequencing, which produces variable
read lengths
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methylation call sets for every replicate to a given mean coverage value. Downsampling
can be done by either filtering the number of reads in an alignment (BAM files), or by
randomly removing a fraction of observed cytosines and observed thymines per CpG
within methylation call sets (bedGraph files). Because downsampling at the alignment
level can be slow and demanding in terms of disk space and compute time, we set out
to evaluate if the signal from downsampling cytosines within bedGraph files recapitu-
lated downsampling aligned reads within BAM files. The two approaches yielded simi-
lar results in number of CpG sites detected, distribution of read counts, and
methylation calls. bedGraph downsampling had the added benefit that the targeted
average CpG coverage was more accurately estimated than when downsampling BAMs
(Additional file 1: Figure S5).
We proceeded with methylation call sets that were normalized to a mean of 20×
coverage per site. Unless otherwise noted, these call sets comprised merged replicates
per library type, and merged calls on positive and negative strands (i.e., reporting
methylation at the dinucleotide level rather than individual cytosines), and in the case
of TrueMethyl libraries, merging the bisulfite-only (BS) and bisulfite-plus-oxidation
(OX) replicates. The mean coverage per library shifted as expected, indicating the suc-
cess of the down sampling approach (Additional file 1: Figure S6a, showing HG003 rep-
licates to demonstrate). Notably, the methylation percentage distribution also shifted,
with the bimodal peaks at 0% and 100% becoming more pronounced, and putatively
hemimethylated regions dropping out as a function of fewer observations per site
resulting in lowered sensitivity (Additional file 1: Figure S6b). We observed that down-
sampling below 20× exaggerated this effect. Downsampling also produced an assay-
specific pattern of site dropout (Additional file 1: Figure S7). Although the overwhelm-
ing number of sites are covered by all assays, we observed the highest CpG dropout in
Table 2 Summary statistics of mapping and library efficiency per WGBS protocol. Percent CpG
capture calculated with call sets normalized to 20x coverage. The total genome-wide CpGs under
consideration were those that could be mapped to uniquely, excluding any CpGs that fall within
unresolvable regions
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TruSeq, followed by SPLAT, then MethylSeq, then TrueMethyl, then EMSeq, both
when accounting for any coverage at all (≥ 1×) or coverage of ≥ 50% of the overall
mean value.
Even after normalizing for mean CpG coverage, we observed a range of assay-specific
empirical cumulative distributions (Fig. 2a). In particular, TruSeq produced left and
right tails of very low and very high coverage. This had an effect on reproducibility be-
tween replicates of the same assay (Fig. 2b), where, compared to an expected distribu-
tion of cross-replicate concordance, TruSeq showed the highest variation, followed by
TrueMethyl, while SPLAT, MethylSeq, and EMSeq were more reproducible than ex-
pected. Intra-assay coverage reproducibility was relatively consistent above 20× cover-
age (r > 0.98 for all assays), but became less consistent below 10× (r ≤ 0.95 for all
assays). We therefore recommend 20× as a minimum CpG dinucleotide coverage value
(Additional file 1: Figure S9).
We restricted further analyses to Chromosome 1, which represents a significant portion
of the genome (10%), contains most difficult regions (such as tandem duplications and
satellites), and is computationally much more tractable than a genome-wide analysis.
When aligning CpGs covered in the 20× downsampled libraries, we found that the major-
ity of CpGs (> 90%) were covered by all assays, with some assay-specific dropout (Fig. 2c).
Nanopore sequencing was able to cover the highest number of CpGs not covered by other
assays, and TruSeq missed the highest number of CpGs covered by other assays (Fig. 2d).
Among the regions covered uniquely by Nanopore sequencing, about 20% were relevant
for epigenetic regulation (promoter, TSS, or exonic sites), while the few CpGs uniquely
captured by other assays were intronic or intergenic (Fig. 2d). Despite the small number
of differences of CpG coverage observed between assays, the genomic annotation of sites
covered was highly consistent (Additional file 1: Figure S8).
We also examined the coverage of CpG islands, shelves, and shores (Fig. 2e). Nano-
pore returned the most even coverage across these annotations, while TruSeq showed
elevated coverage relative to its overall mean in these GC-rich regions. EMSeq, Methyl-
Seq, and SPLAT returned reduced coverage in CpG islands relative to their mean CpG
coverage. This pattern was recapitulated around transcript start sites (TSS), where Tru-
Seq was overrepresented, Nanopore and TrueMethyl stayed relatively flat, and EMSeq,
MethylSeq, and SPLAT were respectively underrepresented in TSS (Fig. 2f).
Methylation across genomic CpGs
After comparing coverage of CpGs, we examined estimates of per-site methylation
across assays. As expected, we found methylation percentages to be bimodally distrib-
uted with peaks near 0% and 100% methylation. All assays exhibited enrichment for
fully methylated regions (Fig. 3a), with the exception of Nanopore, which showed un-
derrepresentation of fully methylated regions, a current limitation of the underlying
base modification calling method (see “Methods”). For short-read approaches, we cal-
culated and corrected for methylation bias (or “mbias”), a measurement of overinflated
hypo- or hyper-methylation signal toward the 5′ and 3′ ends of reads. Mbias analysis
revealed assay-specific deviation at read ends (Fig. 3b). We trimmed bases uniquely for
each sample where values began to inflate as recommended by MethylDackel. Mbias
analysis also revealed overall methylation trends, with SPLAT and EMSeq tending to
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have the highest average methylation across reads, while TrueMethyl had the lowest
among short-read protocols, and TruSeq was the most variably methylated per base
across reads.
Fig. 2 Coverage of CpGs across the genome. All samples visualized here were downsampled to 20× mean
coverage per CpG. a Empirical cumulative distribution functions for median coverage, averaged across
samples for HG002-HG007. b Standard deviation between replicate beta values for HG002 as a function of
average coverage. The expected curve (computed based on the assumption that replicate beta values are
independent and identically distributed estimates of a common proportion p) is added as a solid black
curve. c Intersection of CpG coverage (min 5×) across Chromosome 1. Exact values of CpGs covered per
assay are shown on the right. d Count and genomic annotation for CpGs uniquely covered by an assay
(left) and uniquely not covered by an assay (right). Up5kb = 5 kb upstream distance from promoter region;
Promoter = within 1 kb upstream of transcript start site. e Distribution of coverage in CpG shelves, shores,
and islands. EM = EMSeq; MS = MethylSeq; SP=SPLAT; TS = TruSeq; TM = TrueMethyl. f Mean coverage
curves around transcript start sites (TSS)
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We next assigned genomic features to each CpG and summarized methylation across
regions in a metagene plot (Fig. 3c). As expected, we found that methylation levels
dropped significantly at TSS and then rose again beyond the 5′UTR in all assays. As
detected in the global analysis, methylation captured by Nanopore was lower than by
short-read assays. Nevertheless, all assays including Nanopore showed highly similar
methylation profiles around transcript start sites (TSS) genome-wide (Fig. 3d). Correl-
ation of methylation values across genome-wide CpGs was very high (Fig. 3e). How-
ever, concordance broke down among all assays when restricting to sites with 20–80%
methylation, where correlations were as low as r = 0.42 between Nanopore and TruSeq
(Fig. 3f). Therefore, the majority of disagreement between assays fell in CpG sites that
were either hemimethylated, clonally complex, or undercovered with respect to the glo-
bal mean. Although short-read protocols had higher concordance with one another (r
> 0.93 for all pairwise short-read comparisons) than with Nanopore estimates, we
found that methylation estimation from Nanopore base modification calling was com-
parable to short-read protocols, with Pearson correlation values around r = 0.90 for all
pairwise comparisons (Fig. 3g).
Family trio differential methylation
Differential methylation was examined at the family trio level. For each methylome assay,
we used the replicate-combined methylation calls (including merging bisulfite and oxida-
tive bisulfite replicates for TrueMethyl) that were normalized to 20× mean coverage.
A total of 2,298,846 CpG sites were present on Chromosome 1 in all six assays
(EMSeq, MethylSeq, Nanopore, SPLAT, TrueMethyl, and TruSeq). Coverage levels on
HG002 were positively correlated among EMSeq, MethylSeq, and TrueMethyl (Spear-
man’s ρ ≥ 0.24). SPLAT coverage was also correlated with these three assays as well as
with TruSeq, which was only weakly correlated with any other assay. Nanopore cover-
age was uncorrelated with that of any other assay. The magnitude of pairwise coverage
correlations within each assay varied considerably, with the highest levels observed for
TruSeq (0.85 ≤ ρ ≤ 0.86), SPLAT (0.62 ≤ ρ ≤ 0.71), and MethylSeq (0.47 ≤ ρ ≤ 0.48),
and the lowest for Nanopore (0.14 ≤ ρ0.22), EMSeq (0.28 ≤ ρ ≤ 0.31), and TrueMethyl
(0.32 ≤ ρ ≤ 0.34).
For each assay, differential methylation analysis was independently conducted at the
family level (Ashke nazi Trio HG002-HG004 against the Chinese Trio HG005-HG007).
This also included a restriction to sites with 5× coverage in at least two out of three
members of each family group, resulting in small data reductions for EMSeq, Methyl-
Seq, Nanopore, SPLAT, and TrueMethyl (3%, 4%, > 1%, 4%, and 3%, respectively), and
a greater loss for TruSeq (14%). Comparative analysis considered only the 1,928,536
CpG sites that met this criterion for all six assays. To assess consistency in sites identi-
fied as differentially methylated (DM) by each assay (DMA), we computed the fraction
of DMA sites that were unique to each assay (a pseudo false-positive rate) (Additional
file 2: Supplementary Table 3). We also computed the total number of DM sites com-
monly identified by four or more assays (DM4+), which totaled 1.5% of the common
sites. We then determined the percentage of DMA sites that were also DM4+ sites (a
measure of specificity), as well as the percentage of DM4+ sites that were also DMA
sites (a measure of sensitivity).
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Fig. 3 Estimates of methylation per CpG across the genome for HG002. All samples visualized here were
downsampled to 20× mean coverage per CpG. a Methylation percentage distributions per assay. b
Methylation bias (mbias) plots showing mean methylation per base for short-read assays (Nanopore
excluded here). Dotted lines indicate recommended cutoffs for methylation calling for these data. Original
top/bottom refer to mappings to bisulfite-converted strands in the reference genome. c Metagene plot
showing mean methylation across genomic feature per assay. Promoter regions span 1 kb upstream of
transcript start sites (TSS). d Mean methylation curves surrounding TSS across all genes. e Pearson
correlation matrix of genome-wide methylation estimates. f Pearson correlation matrix of methylation
estimates for sites where methylation was estimated to be between 20 and 80%. g Methylation percentage
correlation between Oxford Nanopore and all other assays. Pearson correlation values shown on top.
Marginal histograms show methylation curves per assay
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For EMSeq, 26% of the sites identified as DM were unique to that assay, comparable
to MethylSeq (26%) and SPLAT (29%). These three assays were also comparable in the
percentage of DM sites that were identified in at least three other assays (36%, 38%,
and 35% for EMSeq, MethylSeq, and SPLAT, respectively), and in the percentage of
DM sites called by at least three other assays that they also detected (90%, 86%, and
89%, respectively). TrueMethyl detected fewer DM sites overall, with 22% of sites
unique to this assay and 42% detected in at least three other assays. However, this did
not correspond to a large decline in sensitivity, as 85% of the sites detected by three or
more other assays were also identified by TrueMethyl. The smallest number of DM
sites was identified in the Nanopore samples, with high specificity (17% unique DMAs
and 56% of sites in DM4+) and lower sensitivity, identifying only 51% of the sites iden-
tified by four or more other assays. TruSeq, on the other hand, was associated with the
largest number of DMA sites and had poor agreement with the other assays, with 43%
unique sites, 38% of its sites identified in two or more other platforms, and only 71% of
the sites identified by three or more platforms among its DMAs.
Figure 4 illustrates the role of coverage variability for each platform. For each assay,
the range between the 5th and 95th percentile of median coverage is shown along the
x-axis, while the degree of agreement with other assays for DM sites is shown along the
y-axis. We see that agreement declines at higher coverage levels, but this effect is min-
imal for EMSeq, MethylSeq, Nanopore, and TrueMethyl. Because SPLAT has a more
heavy tailed coverage distribution with stronger sample-to-sample correlations, the im-
pact is more pronounced, while for TruSeq the coverage distribution is extremely dif-
fuse and there is markedly poor agreement with other platforms in its upper coverage
percentiles.
Normalization of array data
In addition to bisulfite sequencing, microarrays are another commonly used technique
to interrogate the DNA methylation. For each cell line, across three laboratory sites, we
generated 3–6 biological or technical replicates with microarray data from the Illumina
MethylationEPIC Beadchip (850k array) (Table 1). As a first step before integrating
microarray data with the sequencing data, we assessed the performance of different
microarray normalization pipelines.
We implemented 26 normalization pipelines with different combinations of between-
array and within-array normalization methods. The between-array normalization
methods evaluated were no normalization (None), quantile normalization (pQuantile)
[17], functional normalization (funnorm) [18], ENmix [19], dasen [20], SeSAMe [21],
and Gaussian Mixture Quantile Normalization (GMQN) [22]. The within-array
normalization methods evaluated were no normalization (None), Subset-quantile
Within Array Normalization (SWAN) [23], peak-based correction (PBC) [24], and Re-
gression on Correlated Probes (RCP) [25]. All combinations were implemented with
the exception of pQuantile + SWAN and SeSAMe + SWAN, which were not possible
due to incompatible R object types.
We first performed principal component analysis (PCA) and visually inspected the
first two principal components (PCs) for each normalization pipeline (Additional file 1:
Figure S10). Generally, samples from the same cell line clustered together more tightly
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after normalization, although a few pipelines (PBC alone, GMQN alone, GMQN +
PBC) did not show obvious improvement in replicate clustering. Most pipelines failed
to clearly distinguish samples from cell lines HG005 and HG006, the Han Chinese
father/son pair, from one another.
A variance partition analysis was used to compute the percentage of methylation vari-
ance explained by cell line, lab, or residual variation at each CpG site in each normal-
ized dataset. A superior normalization pipeline would have more variation explained by
cell line across the epigenome compared to other pipelines as well as clear clustering of
biological and technical replicates.
Funnorm + RCP had the highest median across the epigenome (90.4%), although
many pipelines had medians in the 85–90% range (Fig. 5a). SeSAMe and RCP per-
formed well (median > 85%) no matter which methods they were combined with. While
using RCP or SWAN usually improved performance compared to having no within-
array normalization, using PBC for within-array normalization always reduced the me-
dian variance explained by cell line. For all downstream analyses, we used the funnorm
+ RCP normalized microarray data because this pipeline had the highest median vari-
ance explained by cell line. Figure 5a shows the full distribution of variance explained
by cell line across the epigenome for each normalization pipeline. Most pipelines had a
bimodal distribution, so CpG sites typically had almost no variation explained by cell
line or nearly 100% of variation explained by cell line.
Fig. 4 Mosaic plots illustrating agreement between assays for differentially methylated per assay (DMA)
sites as coverage levels vary. Rows represent the number of the six assays for which each DMA site was also
identified, with values ranging from 1 (indicating no other assays, shaded in red) to 6 (indicating all assays,
shaded in purple). Columns indicate the median coverage across HG002-HG007, with values ranging
between the 5th and 95th percentiles for each assay
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In light of previous work that has shown that microarray data is not reliable for sites
with low population variation [26], we investigated whether sites with poor concord-
ance between replicates (% variance explained near 0) overlapped with low-varying
sites. We used the 59 SNP probes on the Illumina EPIC array to compute a data-driven
threshold for categorizing sites as low varying (Fig. 5b-d; see “Methods” for details). We
found that nearly all CpG sites in the normalized (funnorm + RCP) microarray data
with poor concordance between replicates met our definition of low-varying sites (Fig.
5e). This suggests that our data-driven definition of low-varying CpG sites, which can
be applied to any Illumina 450k or 850k array dataset, may be useful for filtering out
less reliable CpG sites before analysis.
Normalized microarray concordance with sequencing data
We performed 6 additional variance partition analyses, adding samples from one se-
quencing assay (EMSeq, MethylSeq, SPLAT, TrueMethyl, TruSeq, or Nanopore) at a
time, to evaluate the concordance between microarray and downsampled 20× sequen-
cing data. For each site and each sequencing assay, we estimate the percentage of
methylation variance explained by cell line, assay (sequencing or microarray), and re-
sidual variation. A higher percentage of variance explained by cell line indicates better
agreement with the microarray data.
Ternary density plots of the variance explained by cell line, assay, or residual variation
show lower concordance between the Nanopore sequencing data and the microarray
data than other sequencing assays (Fig. 6a). The five other sequencing assays (EMSeq,
MethylSeq, SPLAT, TrueMethyl, and TruSeq) have a high density of sites where nearly
100% of the methylation variance in the merged sequencing/microarray dataset is ex-
plained by cell line. However, for all assays, there is a smaller peak of CpG sites where
nearly 100% of the methylation variance is explained by assay, indicating that there
were some technical artifacts introduced by assay, but these technical artifacts were not
widespread across the epigenome.
We investigated what was driving poor concordance between assays at this subset of
CpG sites and found a strong, non-linear relationship between the amount of variability
at a CpG site and concordance (Fig. 6b). The non-linear relationship between CpG site
variance in the microarray data and concordance between assays indicates that there is
a minimum amount of population variance needed for reproducibility, but beyond this
threshold more variation does not improve concordance. This confirms our proposed
approach of estimating technical noise from the SNPs on the array to create a binary
“low-varying” or “high-varying” classification for CpG sites.
Because each cell line had 3–6 microarray replicates and only one (merged replicate)
sequencing sample, these results are largely driven by the microarray data and the esti-
mates of the percentage of variation explained by cell line (vs. assay) are likely biased
upward by this. Visual inspection of the joint distribution of microarray and sequencing
beta values for all HG002 replicates (with sequencing replicates from the same lab
merged) shows that there is substantial technical noise in the data when comparing any
two assays (Additional file 1: Figure S11). For the same assay in two different labs, we
see much better concordance between HG002 beta values with microarrays than with
EMSeq.
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Differential methylation in microarray sites
We took differentially methylated regions between family groups (see above) and re-
stricted them to sites captured by the Illumina MethylationEPIC Beadchip (850k array)
(see above). Of the 82,013 probes on the array that map to regions on Chromosome 1,
81,456 sites (99.3%) were detected at high depth by all six sequencing assays. Of these,
the number of differentially methylated assays (DMAs) ranged from 1027 (Nanopore)
to 4267 (TruSeq). For EMSeq, MethylSeq, Nanopore, and TrueMethyl, over 99% of
these DMA had estimated percent methylation difference (PMD) of 20% or greater
Fig. 5 Microarray normalization and low-varying site definition. a Densities showing the percentage of DNA
methylation variation explained by cell line across the epigenome (N = 677,520 overlapping CpG sites) for
each normalization method. b Raw beta values at each of the 59 SNP probes on the Illumina EPIC arrays,
with samples colored by lab. c Variance in methylation beta values (no normalization) within each
genotype cluster at the 59 SNP probes, separated and colored by lab. The dotted vertical line represents
the 95th percentile. d Variance in methylation beta values (normalized with funnorm + RCP) across the
epigenome. Sites in the shaded area, which have less variation than 95% of SNP probe genotype clusters,
are defined as low-varying sites. e Percentage of methylation (normalized with funnorm + RCP) variance
explained by cell line across the epigenome, stratified by high-varying vs. low-varying sites
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between the family groups, while 95% and 80% of DMAs met this criterion for SPLAT
and TruSeq, respectively.
To analyze concordance between the sequencing-based and array results, we com-
puted the proportion of these DMAs for which a corresponding difference of at least
20% was observed for the arrays, with these array PMDs estimated via ANOVA models
with random intercepts for each genome. As illustrated by Additional file 2: Supple-
mentary Table 4, the overall agreement was comparable for four of the six methods
with values ranging from 55.5% (EMSeq) to 60.0% (TrueMethyl), with a higher level of
67.0% for Nanopore and a lower level of 49.6% for TruSeq. However, among the 4137
sites with array |PMD| > 0.2, only 16.6% were Nanopore DMAs in comparison to 42–
44% for all other assays, suggesting high precision but lower sensitivity for this assay.
Discussion
The EpiQC study provides a comprehensive epigenetic benchmarking resource using
human cell lines established by the Genome in a Bottle Consortium as reference mate-
rials to advance genomics research. We provide datasets for a broad range of methy-
lome sequencing assays, including short-read whole-genome bisulfite sequencing
(WGBS) and enzymatic deamination (EMSeq), and native 5-methylcytosine calling
using Oxford Nanopore long-read sequencing. We also provided data from targeted ap-
proaches, including reduced representation bisulfite sequencing (Methyl Capture EPIC),
methylated DNA immunoprecipitation and sequencing (MeDIP-seq) for mC and hmC,
and the Illumina Infinium MethylationEPIC 850k array. While most of the published
and/or commercialized assays have been tested with some standard samples (e.g.,
GM12878), the sample used to benchmark each assay was drawn from different DNA
aliquots, extracted from cells grown at different passages, and potentially grown in dif-
ferent media. Here, aliquots of the same gDNA were distributed across multiple labora-
tories and used for all data generated. To remove additional variability, all libraries
were sequenced on multiple flow cells of one Illumina NovaSeq 6000 (then a third flow
cell on the same instrument type). For all assays, libraries were produced in duplicates,
providing both inter- and intra-assay datasets.
Benchmarking whole methylome sequencing technologies is important for determin-
ing which method will achieve the best performance, and to provide recommendations
and standards for experimental design within future studies. Large projects such as the
NIH Roadmap Epigenomics Project [27], the International Human Epigenome Consor-
tium [28], and the Cancer Genome Atlas [29] have produced, compiled, and analyzed a
vast amount of WGBS data comprising tissues and cell lines from normal and neoplas-
tic tissues. Building upon these previous works, our study encompasses an up-to-date
range of commonly used whole methylome assays as well as emerging methods such as
enzymatic methylation and native 5mC calling from long-read technologies and pro-
vides data across 7 different reference material cell lines, providing a comprehensive
examination of DNA methylation analysis methods.
We found that the library preparation method of choice and parameters used within
each protocol can significantly impact data quality and utility for biological interpreta-
tions. Libraries with longer inserts benefited from less adapter contamination, fewer
dovetailing (overlapping) reads, and fewer low-quality bases, which increased mapping
efficiency and mean coverage per CpG. This is particularly impactful when one chooses
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Fig. 6 a Density plots of sequencing/microarray concordance indicating the percent of variance explained
(VE) by cell line, assay (sequencing or microarray), and residual variation for 841,833 CpG sites with
complete information in all assays. b Distribution of percent variance explained by cell line in the
sequencing/microarray variance partition analysis as a function of beta value variance (binwidth = 0.001)
and median coverage (binwidth = 1) at each CpG site. 90% of the y-axis values fall between the outermost
dotted lines for each bin along the x-axis
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to employ a cost-effective sequencing on an Illumina system with paired-end 150 bp
reads, as was done within this study. This sequencing scheme resulted in a highly vari-
able depth of coverage per library preparation. While imbalanced pools may account
for some of the difference, library preparation methods had the biggest impact. Except
for TruSeq, all the other library preparations start with shearing of the gDNA. For the
other bisulfite-dependent protocols, the DNA fragments range between 200 and 400,
whereas EMSeq allows for longer fragments (550 bp). TruSeq libraries tend to have
short (130 bp) insert sizes and are therefore more suitable for 75 bp paired-end read
lengths. To overcome the impact of imbalanced sequence depth, this study provides ro-
bust recommendations for downsampling across sequencing types, showing both how
different downsampling schemes (i.e., at the BAM level or at the methylation bedGraph
level) are comparable, and how downsampled datasets can be directly compared to one
another to assess the performance of the assays themselves.
The methods that have proven to have greater genome-wide evenness of coverage,
namely Accel-NGS MethylSeq [15], SPLAT [6], and TrueMethyl [30], tend to have lon-
ger insert sizes (200–300 bp), fewer PCR duplicates (down to a few percent, depending
on sequencing platform), and high mapping efficiencies (> 75%). The SPLAT libraries
herein had shorter insert sizes than desired due to the use of 400 bp Covaris shearing
prior to library preparation. To achieve insert sizes of ≥ 300 bp, the SPLAT authors
now recommend using DNA fragmented to 500–600 bp as input and to perform final
library purification at 0.8× AMPure ratio to remove shorter fragments. The same rec-
ommendation may also improve the insert size for MethylSeq and TrueMethyl proto-
cols. SPLAT is the only method in our evaluation that is not commercial/kit-based and
could be comparatively ~ 10× cheaper per library [6]. This can be important when con-
sidering the sample preparation cost alongside sequencing costs.
The EMSeq protocol [31] compares favorably to the bisulfite sequencing-based ap-
proaches analyzed herein. In almost all comparisons, EMSeq libraries capture more
CpG sites at equal or better coverage. We also show that the methylation signal
achieved by native base modification detection from Oxford Nanopore long-read se-
quencing is highly comparable to short-read bisulfite- and enzymatic-methylation se-
quencing, with average Pearson correlation values of r = 0.90 for CpG methylation
concordance. Moreover, Nanopore can detect a significant number of sites that short-
read assays miss, many of which occur in promoter and exonic regions that are poten-
tially of biological significance.
Beyond library preparation, the use of algorithmic tools has an impact on the per-
formance of each methylome assay. Asymmetrical C-T distributions between DNA
strands and reduced sequence complexity make epigenetic sequence alignment differ-
ent from regular DNA processing. We compared common methylation processing
pipelines and compared their mapping efficiencies, depth of coverage achieved per
CpG, and computational time to run, and observed bwa-meth to provide the best per-
formance when considering all of these factors. Notably, BitMapperBS was faster than
bwa-meth, and not far behind in mapping efficiency and CpG coverage.
Another important parameter is the amount of data retained from a WGBS experi-
ment following adapter and quality trimming, mapping, and de-duplication. Here, we
show the effects of each mapping step on each methylome assay (Additional file 1: Fig-
ure S4), and how reads are filtered along each step, including the estimated number of
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reads required to achieve a certain mean coverage per CpG (Table 2). Similarly, previ-
ous studies [5, 15] have implemented a metric to estimate the efficiency of WGBS gen-
ome coverage by determining the raw library size (number of PE 150 bp reads prior to
filtering) required to achieve at least 30× coverage of 50% or more of the genome. We
propose a modified version of the calculation proposed by Zhou and colleagues, deriv-
ing the number of PE150 bp reads needed to achieve 20× average CpG coverage for a
library, as this metric directly relates back to the CpG sites whose methylation levels
will be interrogated. We also calculate usable bases, reflecting the total bases used for
methylation estimation out of the total bases sequenced per library. Adoption of such
metrics will make it significantly easier to compare and contrast results from different
methods.
Choice of computational algorithms is equally important in analyzing methylation
microarray data as the data generation. In this study, we compared 26 different
normalization pipelines. Many algorithms (SWAN, RCP, pQuantile, dasen, funnorm,
ENmix, SeSAMe) generally performed well in this dataset, clustering replicates from
the same cell line together while preserving differences between cell lines. Given the
comparable performance of these methods, the best normalization pipeline will depend
on the needs of individual studies. For instance, cohorts with multiple tissues may want
to use the multi-tissue extension of funnorm, funTooNorm [32], and cohorts with very
large sample sizes may want to use SeSAMe [21], which is the only single-sample
normalization method we evaluated. All pipelines performed poorly at sites with low
population variance, confirming previous work [26]. We propose using the SNPs on
the 850k array to calculate a data-driven threshold for classifying and filtering out low-
varying sites before analysis. Previously published associations at sites with low popula-
tion variation, which can also often be identified by their extreme (< 5% or > 95%) me-
dian methylation values [26], should be interpreted with caution. Additionally, our data
from EM-Seq and microarray replicates across different labs (Additional file 1: Figure
S11) support previous findings that the Illumina 850k array was more reproducible
than TruSeq across paired technical replicates from 4 cord blood samples [33]. We
conclude that overall, microarrays are a good option for researchers who are comfort-
able with a targeted assay.
One final caveat for the data within this study is our use of high-quality DNA from
EBV-immortalized, B-lymphoblastoid cell lines. Using this highly controlled input, the
methods examined within this study produced mostly comparable data. However, the
performance of each kit may be more variable on less optimal input DNA (lower input,
more highly fragmented, etc.) that mirrors real clinical samples more closely. The opti-
mal data herein should serve as a launch point for future studies of more realistic
inputs.
Summary items
(1) We provide DNA methylation data for epigenomic benchmarking across seven cell
lines designated as reference materials by the Genome in a Bottle Consortium for
furthering genomics research. These data are publicly available within NCBI SRA
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under accession numbers SRR13050956–SRR13051274, and the code used to
analyze and visualize the data is fully available at https://github.com/jfoox/epiqc.
(2) We recommend the use of bwa-meth for reference-based alignment of bisulfite
data, followed by MethylDackel for methylation estimation, based on a combin-
ation of computational time required and mapping efficiency.
(3) Although there are characteristic differences between whole genome methylation
library preparations, they are highly concordant for 5mC characterization. There is
almost no detectable 5-hydroxymethylcytosine in these cell lines and they are not
recommended for benchmarking 5hmC.
(4) We provide estimates of how many reads are required per protocol to reach 20×
mean coverage of genome-wide CpGs (Table 2). Enzymatic deamination reactions
(EMSeq) are as efficient or better as bisulfite methods are. For all library prepar-
ation types, we recommend longer insert sizes, especially for 2 × 150 bp sequencing
chemistries.
(5) The concordance of nanopore sequencing and native base modification calling
with enzymatic/chemical conversion methods (r = 0.92) has improved considerably
and will continue to improve with newer base modification models. Nanopore data
can also be used to characterize many thousands of CpGs that are inaccessible to
short-read data types. Areas of disagreement between modalities typically involve
estimates of complete methylation in short-read bisulfite data that are more het-
erogeneous (5mC% at 75–90%) in long-read nanopore data.
(6) For normalization of microarray data, non-sample variance is best minimized using
a combination of Funnorm and RCP (though many pipeline combinations per-
formed comparably with medians in the 85–90% range).
(7) We propose using the SNPs on the 850k array to calculate a data-driven threshold
for classifying and filtering out low-varying microarray sites before analysis. Associ-
ations at sites with low population variation should be interpreted with caution.
(8) Beta values from microarrays and base-level methylation estimates from sequence
data are highly comparable. Variance between the two in shared sites is almost en-
tirely sample-specific and likely reflective of technical noise.
Study limitations
There are several limitations to the experimental design within this study. First,
the low number of replicates per protocol per cell line limited our ability to distin-
guish assay-specific signal from technical noise. Second, not all laboratories in-
volved in the study used the same set of positive and negative control spike-ins
(fully methylated pUC19 plasmid and fully unmethylated lambda phage), which
limited our ability to directly compare the quality and efficiency of each library
preparation type. Finally, the imbalanced library pooling and loading onto flow cells
led to a wide range of data generated per library, which resulted in low coverage
for some replicates, and in several cases below the minimum we recommend for
methylation analysis. This forced us to compare protocols with replicates merged,
which further limited our ability to analyze variability within each protocol. Thus,
there is room for future studies to build upon and expand these data to further
address questions of reproducibility.
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Methods
Genomic DNA
The samples in this study comprise genomic DNA (gDNA) from seven EBV-
immortalized B-lymphoblastoid cell lines designated as reference samples by the Na-
tional Institute of Standards and Technology (NIST) Genome in a Bottle Consortium
(see https://www.coriell.org/1/NIGMS/Collections/NIST-Reference-Materials). The
NA12878 (HG001) cell line was selected as it is the most commonly used reference for
benchmarking or generation of genomics datasets. Additionally, six cell lines represent-
ing two trios from the Personal Genome Project, which are consented for commercial
redistribution, were also included. The HG002/3/4 samples were provided by a son/
father/mother trio of Ashkenazi Jewish ancestry, and the HG005/6/7 come from a Han
Chinese son/father/mother trio.
For each reference cell line, 100 μg genomic DNA (gDNA) was purchased from the
Coriell Institute for Medical Research, along with viable cell lines for later growth and
distribution. The gDNA was quantitated using Qubit Broad Range dsDNA kit and an
aliquot from reference sample gDNA was distributed to six independent laboratories
for NGS library preparation or microarray analysis.
NGS library preparation
Enzymatic Methyl-Seq (EMSeq)
EMSeq libraries were prepared at two different laboratories using slightly altering pro-
tocols. At Lab1, genomic DNA was spiked in with 2 ng unmethylated lambda as well as
0.1 ng CpG methylated pUC19, and was then fragmented to 500 bp using a Covaris S2
(200 cycles per burst, 10% duty-cycle, intensity of 5, and treatment time of 50 s). At
Lab2, genomic DNA was fragmented to 450 bp using Covaris 130 μL. While all repli-
cates of HG001-004 were created using 100 ng of DNA, both labs created replicates of
HG005-007 using 100 ng, 50 ng, and 10 ng of DNA in order to test the effects of input
concentration. EMSeq libraries from both laboratories were prepared using the NEB-
Next Enzymatic Methyl-Seq (E7120, NEB) kit following the manufacturer’s instruc-
tions. Final libraries were amplified with NEBNext Q5U polymerase using 4 PCR cycles
for 100 ng, 5 cycles for 50 ng, and 7 cycles for 10 ng inputs. Libraries were quality con-
trolled on a TapeStation 2200 HSD1000.
Swift Biosciences Accel-NGS Methyl-Seq (MethylSeq)
Libraries were prepared according to the manufacturer’s instructions (Swift) using
dual-indexing primers. Briefly, 100 ng of genomic DNA was spiked in with 1%
unmethylated Lambda gDNA and fragmented to 350 bp (Covaris S220, 200 cycles
per burst, 5% duty factor, 175W peak displayed power, duration of 50 s). Bisulfite
conversion was performed using EZ DNA Methylation-Gold kit (Zymo Research).
Adaptase was used to ligate adapters to the 3′ end of the bisulfite-converted DNA,
followed by primer extension, second strand synthesis, and ligation of adapter se-
quences at its 3′ end. The libraries were amplified for a total of 6 rounds using
the Enzyme R3 provided with the kit. Libraries were quality controlled on a TapeS-
tation 2200 HSD1000.
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SPlinted Ligation Adapter Tagging (SPLAT)
In total, 100 ng gDNA was fragmented to 400 bp (Covaris E220, 200 cycles per burst,
10% duty factor, 140 peak incident power PIP, 55 s treatment time). Bisulfite conversion
was performed using the EZ DNA Methylation-Gold kit (Zymo Research). SPLAT li-
braries were constructed as described previously [6]. Briefly, adapters with a protruding
random hexamer were ligated at the 3′ end and 5′ end of single-stranded DNA in con-
secutive reactions. The resulting libraries were amplified with 4 PCR cycles using
KAPA HiFi Uracil+ PCR enzyme (Roche). Libraries were quality controlled on a TapeS-
tation 2200 HSD1000.
NuGEN TrueMethyl oxBS-Seq (TrueMethyl)
In total, 200 ng of genomic DNA was spiked with 1% unmethylated Lambda gDNA and
fragmented to 400 bp (Covaris S220, 10% duty factor, 140W peak incident power, 200
cycles per burst, duration of 55 s). Fragmented DNA was processed for end repair, A-
tailing, and ligation using NEB’s methylated hairpin adapter. Ligation was performed at
16 °C overnight in a thermocycler. The USER enzyme reaction was performed the next
morning, according to the manufacturer’s protocol, and the adapter-ligated DNA
cleaned up using 1.2:1 Ampure XP bead:ligated DNA ratio. Each ligation was then split
into 2 aliquots to perform oxidation + bisulfite conversion or mock (water) + bisulfite
conversion according to the OxBS module instructions (Tecan/NuGen). PCR amplifica-
tion was performed using NEB’s dual-indexing primers and KAPA Uracil+ HiFi enzyme
for a total of 10 cycles. Libraries were quality controlled on a TapeStation 2200
HSD1000.
Illumina TruSeq DNA Methylation (TruSeq)
In total, 100 ng of genomic DNA was bisulfite converted using EZ DNA Methylation-
Gold Kit (Zymo Research). Sequencing libraries were prepared according to the manu-
facturer’s protocol (Illumina). Briefly, the bisulfite-converted DNA was first primed by
random hexamers containing a tag sequence on its 5′ end. Next, the bottom strand
was extended and a 3′ end oligo added. The libraries were amplified with 10 PCR cy-
cles using the FailSafe PCR enzyme (Illumina/Epicentre). Libraries were quality con-
trolled on a TapeStation 2200 HSD1000.
Illumina Methyl Capture EPIC
In total, 500 ng of genomic DNA was prepared according to the manufacturer’s proto-
col (Illumina), including a spike-in of 2 ng of unmethylated lambda. Briefly, the gen-
omic DNA was fragmented to 200 bp using a Covaris S220 (10% duty-cycle, 175W
peak incident power, 200 cycles per burst, duration of 360 s). The fragmented DNA was
next purified using AMpure XP beads, end-repaired, and A-tailed, before ligation of
single index adapters with methylated cytosines. Libraries cleaned using AMpure XP
beads, then pooled in 3- and 4-plex. The pools were denatured to single-stranded DNA
before hybridization to the RNA baits provided with the kit. After cleanups of the hy-
bridizations according to the manufacturer’s protocol, the captured strands were proc-
essed for library amplification by PCR using KAPA Uracil+ HiFi enzyme (Roche) and
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TrueSeq primers included in the kit. Libraries were quality controlled on a TapeStation
2200 HSD1000.
Oxford Nanopore Library Preparation
Genomic DNA was quantified using a Qubit 4 Fluorometer (ThermoFisher Q33238),
and libraries were prepared using a Ligation Sequencing Kit (SQK-LSK109, Oxford
Nanopore Technologies). Briefly, 1000 ng of genomic DNA was end-repaired and dA-
tailed using the NEBNext End Repair/dA-tailing module, and then sequencing adapters
were ligated. DNA fragments below 4 kb were removed using the long fragment wash
protocol option according to the manufacturer’s protocol.
EPIC microarrays
Illumina Infinium MethylationEPIC BeadChip (850k array)
Bisulfite conversion was performed using the EZ DNA Methylation Kit (Zymo Re-
search) with 250 ng of DNA per sample. The bisulfite converted DNA was eluted in
15 μl according to the manufacturer’s protocol, evaporated to a volume of < 4 μl, and
used for methylation analysis on the 850k array according to the manufacturer’s proto-
col (Illumina).
Microarray experiments were run at three different labs, denoted labs A, B, and C to
distinguish them from the sequencing labs (lab 1 and lab 2). The resulting dataset con-
tains 30 samples, with each of the seven cell lines (HG001-HG007) having between
three and six replicates (biological or technical). Two technical replicates were gener-
ated for each cell line at lab A, one replicate from each cell line was generated at lab B,
and three technical replicates were generated for the Han Chinese family trio cell lines
(HG005-HG007) at lab C.
LC-MS/MS quantification of 5mC and 5hmC
Genomic DNA from HG001-007 cell lines was used for the analysis. Samples were
digested into nucleosides using Nucleoside digestion mix (M0649S, New England Bio-
labs) following manufacturer’s protocol. Briefly, 200 ng of each sample was digested in
a total volume of 20 μl using 1 μl of the digestion mix. Samples were incubated at 37 °C
for 2 h.
LC-MS/MS analysis was performed using two biological duplicates and two technical
duplicates by injecting digested DNA on an Agilent 1290 UHPLC equipped with a
G4212A diode array detector and a 6490A Triple Quadrupole Mass Detector operating
in the positive electrospray ionization mode (+ESI). UHPLC was performed on a Wa-
ters XSelect HSS T3 XP column (2.1 × 100 mm, 2.5 μm) using a gradient mobile phase
consisting of 10 mM aqueous ammonium formate (pH 4.4) and methanol. Dynamic
multiple reaction monitoring (DMRM) mode was employed for the acquisition of MS
data. Each nucleoside was identified in the extracted chromatogram associated with its
specific MS/MS transition: dC [M + H] + at m/z 228-112, 5mC [M + H] + at m/z 242-
126, and 5hmC [M + H] + at m/z 258-142. External calibration curves with known
amounts of the nucleosides were used to calculate their ratios within the analyzed
samples.
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DNA sequencing
Illumina sequencing
The short-read sequencing libraries were collected from participating laboratories and
sequenced centrally at two sequencing centers. Libraries were pooled by library type in
high concentration equimolar stock pools (4 nM). After pooling, bead-based clean-up
was performed to remove peaks < 200 bp. The cleaned stock pools were quantified on
an Agilent Bioanalyzer using High sensitivity DNA chip and subsequently diluted to
1.5 nM prior to sequencing on Illumina NovaSeq 6000 S4 flowcells PE150 read length
to a targeted minimum per replicate CG coverage of 20×. Base calling was performed
using RTA v3.4.4. Additional details about the sequencing parameters can be found in
the Supplementary Materials and Methods.
Oxford Nanopore Sequencing
The Nanopore libraries were run simultaneously on seven FLO-PRO002 flow cells for
64 h on a PromethION Beta device to maximize yield. FAST5 files were generated
using default parameters within MinKNOW on the PromethION machine. Base calls
and base modification calls were generated using Megalodon v2.2.9 (https://
nanoporetech.github.io/megalodon/) with guppy v4.2.2 (https://community.
nanoporetech.com/downloads/guppy) as the basecaller backend. The MinION DNA
R9.4.1 5mC configuration file from the Rerio database (https://github.com/
nanoporetech/rerio) was used as the base modification model. The MinION model was
chosen because it maintained more consistent peaks at 0% and 100% methylation as
compared to the PromethION model.
Data quality control
FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) was used to
evaluate the quality of sequencing data, including base qualities, GC content, adapter
content, and overrepresentation analysis. Adapter sequences were trimmed using
FASTP [34] with a minimum length of two bases, quality filtering disabled, and forced
poly-G trimming. The data generated using the Swift Methyl-Seq kit were further
trimmed for an additional 10 bp on the 3′ end of R1 and 10 bp on the 5′ end of R2 to
remove Adaptase sequence introduced during library preparation.
Alignment and methylation calling
Alignment comparison was conducted on sample HG002. All short-read WGBS librar-
ies were aligned to the human reference genome (build GRCh38) with additional con-
tigs included representing bisulfite controls spiked within pooled libraries, including
lambda, T4, and Xp12 phages, as well as cloning vector plasmid pUC19. The Epstein-
Barr Virus (EBV) sequence was also included as a decoy contig to account for use of
EBV to immortalize B-lymphocytic cell lines.
BISMARK
Adapter-trimmed reads were aligned using two parallel instances of BISMARK v0.23.0
(https://github.com/FelixKrper replicate) and bowtie2 (http://bowtie-bio.sourceforge.
net/bowtie2/index.shtml) as the read aligner. BAM files were position sorted using
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sambamba sort (https://lomereiter.github.io/sambamba/) and deduplicated using dedu-
plicate_bismark with default parameters. Methylation was called using bismark_methy-
lation_-extractor using 2 multicore instances and default parameters and strands were
merged into dinucleotide contexts using MethylDackel (https://github.com/dpryan79/
MethylDackel) mergeContext.
BitMapperBS
Alignment was run using default parameters within BitMapperBS v1.0.2.2 on adapter-
trimmed FASTQs and the resulting BAMs were position sorted using sambamba sort.
Alignments were deduplicated using Picard MarkDuplicates (https://broadinstitute.
github.io/picard). Methylation was extracted using MethylDackel extract and strands
were merged into dinucleotide context using MethylDackel mergeContext.
BSSeeker2
Adapter-trimmed reads were aligned across four threads within BSSeeker2 using bow-
tie2 as the aligner per user guide recommendation. Alignments were sorted using sam-
bamba sort and deduplicated using Picard MarkDuplicates. Methylation was called
within bs_seeker2-call_methylation, and strands were merged into dinucleotide con-
texts using MethylDackel mergeContext.
bwa-meth
Adapter-trimmed reads were aligned using bwa-meth v0.2.1 with default parameters
and converted into BAM format using sambamba view. Alignments were then position
sorted with sambamba sort and deduplicated using Picard MarkDuplicates. Methylation
was called with MethylDackel extract and strands were merged into dinucleotide con-
texts using MethylDackel mergeContext
gemBS
gemBS v3.2.0 (https://github.com/heathsc/gemBS) requires two set-up files to enable
analysis. The first file is a metadata sheet, in which sample barcodes were provided in
assay/lab/genome/replicate format (e.g. EMSeq_LAB01_HG001_REP01). The second
file is a configuration sheet, in which default parameters were applied, including MAPQ
threshold of 10, base quality threshold of 13, reference bias of 2, 5′ trim of 5 bp, 3′ trim
of 0 bp, removing improper pairs, marking duplicate reads, diploid alignment, auto con-
version, and all files generated (CpG, non-CpG, bedMethyl, and bigWig). These files
were fed into gemBS which uses GEM3 for alignment and BScall for methylation
calling.
Downsampling methylation calls
The 5-methylcytosine bedGraph files generated by the bwa-meth aligner (see “Results”
for rationale to proceed with bwa-meth calls for secondary analyses) were normalized
such that each call set had a given mean global coverage per CpG. In order to
maximize coverage per library, all technical replicates were combined per library type
per cell line per laboratory (e.g., all replicates for EMSeq HG002 from Laboratory 1
were combined) by summing up the methylated and unmethylated counts per CpG site.
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Next, counts along the positive and negative strands were merged in order to produce
one value per CpG dinucleotide using MethylDackel mergeContext. The resulting
replicate-CpG-merged bedgraphs were downsampled using https://github.com/
nebiolabs/methylation_tools/downsample_methylKit.py where a fraction of counts kept
corresponding to the desired downsampling depth.
To compare downsampling from mapped reads (BAM files) in comparison to bed-
Graph files, the BAM files from all replicates representing EMSeq HG006 (Lab 1) were
respectively merged using samtools merge. The merged BAMs were then downsampled
using samtools view using the −s parameter, calculating the fraction of reads necessary
to achieve the desired mean coverage per BAM. Methylation was called on these BAM
files using the same methodology as above. The strands were merged by CpG dinucleo-
tide using MethylDackel merge context, creating one methylation call per CpG site.
The procedure is outlined in Additional file 1: Figure S5.
Differential methylation
Differential methylation between the two family groups (Ashkenazi Jewish Trio,
HG002-HG004 vs Han Chinese Trio, HG005-HG007) was assessed at each site on
Chromosome 1 for which at least two samples per group were covered by 5 or more
reads. Following aggregation of replicates, strand merging, and down sampling to mean
20× coverage, analysis was independently conducted via logistic region for each of six
platforms (MethylSeq, EMSeq, Nanopore, TruSeq, SPLAT, and TrueMethyl) using the
standard “glm” function in R. p values were adjusted using the Benjamini-Hochberg
correction and adjusted values < 0.05 were considered statistically significant. Compari-
sons among platforms considered only sites that were present for all assays.
Microarray normalization
Microarray normalization methods were divided into two broad categories: between-
array normalization and within-array normalization. Between-array normalization is
used to reduce technical variation while preserving biological variation between sam-
ples, while within-array normalization is used to correct for the two different probe de-
signs on the Illumina methylation arrays, which have been observed to have different
dynamic ranges [24]. The between-array normalization methods evaluated were
pQuantile [17], funnorm [18], ENmix [19], dasen [20], SeSAMe [21], and GMQN [22].
We implemented all possible combinations of between-array and within-array
normalization methods as well as each method individually. Samples from all 3 labs
were normalized together as one joint dataset.
In order to evaluate the performance of each pipeline, all 30 microarray samples from
3 labs were pooled together in a variance partition analysis [35]. For each pipeline and
at each CpG site, the percentage of variation in DNA methylation beta values explained
by cell line and lab was calculated. Additionally, we performed principal components
analysis (PCA) and visually inspected clustering of technical and biological replicates
across all normalization pipelines.
After normalization, we used the 59 SNP probes on the 850k array, meant to identify
sample swaps [36], to define a data-driven classification of low-varying sites. Previous
studies have found that low-varying sites have poor reproducibility on the Illumina
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arrays [26] and have suggested data-driven probe filtering using technical replicates [37,
38] or beta value ranges [26]. However, not all studies have technical replicates, and
previously proposed beta value range cutoffs for one experiment may not be
generalizable to another experiment. We first called genotype clusters based on the
beta values at each of the 59 SNP probes within each of the 3 different labs (Fig. 5b).
Although we used a naïve approach for calling genotypes (< 25% methylation = cluster
1, 25–50% methylation = cluster 2, > 75% methylation = cluster 3), which was sufficient
for the clear separation in our dataset (Fig. 5b), more sophisticated methods [39] can
be used for datasets with less clear separation and/or outlier values. In theory, because
these 59 SNP probes are meant to measure genotypes, cell lines with the same geno-
type should have exactly the same readout in an experiment without any technical
noise. Therefore, we can use variance within genotype clusters from the same experi-
ment as a measure of technical noise and determine the minimum population variation
needed to exceed the observed technical variation. Within each of the 3 labs, we calcu-
lated methylation variance at each SNP probe within each genotype cluster, giving us a
distribution of observed technical noise (Fig. 5c). To avoid being overly conservative
due to outlier values at these 59 SNP probes, we use the 95th percentile of these geno-
type cluster variances as the threshold for defining low-varying sites (Fig. 5c, d).
Sequencing performance in microarray sites
Variance partition analyses [35] were used to compare the microarray and down-
sampled sequencing datasets and assess concordance between microarray and sequen-
cing assays. Each of the variance partition analyses included all microarray replicates,
normalized with funnorm + RCP, and one sequencing sample per cell line with all rep-
licates merged. The percent of variation in DNA methylation explained by cell line,
assay (sequencing or microarray), and residual variation was calculated at each CpG
site. This produced 6 sets of results, one per sequencing assay. The percentage of vari-
ation explained by cell line at each site was used as a measure of cross-platform con-
cordance between each sequencing platform and the microarray data. The variance
partition results presented are restricted to CpG sites that were measured in all 7 cell
lines across all 7 assays (N = 841,883) to ensure a fair comparison.
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